AGENDA
128TH Meeting of the
National Cancer Advisory Board
National Cancer Institute

TUESDAY, DECEMBER 2, 2003 - OPEN
Building 31, C Wing, Conference Room 10

8:00 a.m. - 8:10 a.m.
I. CALL TO ORDER, OPENING REMARKS, and CONSIDERATION OF SEPTEMBER 2003 MINUTES  
Dr. Niederhuber

II. FUTURE BOARD MEETING DATES

Confirmed:
February 17-19, 2004  
June 1-3, 2004  
September 13-15, 2004  
November 29 - December 1, 2004  
February 15-17, 2005  
June 6-8, 2005  
September 19-21, 2005  
December 5-7, 2005  
Tuesday, Wednesday, Thursday  
Tuesday, Wednesday, Thursday  
Monday, Tuesday, Wednesday  
Monday, Tuesday, Wednesday  
Tuesday, Wednesday, Thursday  
Monday, Tuesday, Wednesday  
Monday, Tuesday, Wednesday

8:10 a.m. - 8:40 a.m.
III. DIRECTOR’S REPORT  
Dr. von Eschenbach

8:40 a.m. - 9:10 a.m.
IV. FISCAL 2004 BUDGET UPDATE  
Mr. Hartinger  
Mr. Hazen

9:10 a.m. - 9:30 a.m.
V. PRESIDENT’S CANCER PANEL REPORT  
Dr. Leffall

9:30 a.m. - 9:45 a.m.
VI. LEGISLATIVE UPDATE  
Ms. Erickson

9:45 a.m. - 10:15 a.m.
VII. OVERVIEW: CENTER FOR STRATEGIC DISSEMINATION  
Dr. Maibach
10:15 a.m. – 10:20 a.m.

VIII. SPECIAL RECOGNITION
Dr. von Eschenbach
Dr. Niederhuber

10:20 a.m. - 10:35 a.m.

COFFEE BREAK

10:35 a.m. - 11:05 a.m.

IX. OVERVIEW: OFFICE OF COMMUNICATIONS
Ms. Castro
Ms. Bright

11:05 a.m. - 12:00 noon

X. NANOTECHNOLOGY STRATEGIC INITIATIVES
Dr. Barker
Dr. Ferrari

12:00 noon - 1:15 p.m.

WORKING LUNCH
• Update: Task Force on Advanced Biomedical Technology Initiative
  Dr. Lander

1:15 p.m. - 4:05 p.m.

XI. PROGRAM REVIEW OF CENTER FOR CANCER RESEARCH

1:15 p.m. OVERVIEW
Dr. Barrett

1:30 p.m. FUNDAMENTAL DISCOVERIES IN CANCER
• Role of DNA Breaks in Genomic Instability and Cancer
  Dr. Nussenzweig
• TGF-betas in Cancer Progression: Complex Roles and Therapeutic Opportunities
  Dr. Wakefield

2:20 p.m. NOVEL APPROACHES IN CANCER DETECTION AND DIAGNOSIS
• Mapping Molecular Network Interconnections Using Protein Microarrays for Patient Tailored Therapy
  Dr. Petricoin
• Oncologic Imaging: Anatomic, Functional and Molecular
  Dr. Choyke
3:10 p.m. IMMUNOTHERAPY

- Integrating Immunotherapy into Cytotoxic Regimens: Pediatric Sarcomas as a Model  
  Dr. Mackall
- Design, Development and Delivery of Recombinant Vaccines for the Therapy of Human Carcinomas  
  Dr. Schlom

3:55 p.m. CONCLUDING REMARKS  
  Dr. Barrett

4:05 p.m. - 4:20 p.m.
COFFEE BREAK

4:20 p.m.
ADJOURNMENT OF OPEN SESSION

TUESDAY, DECEMBER 2, 2003 - CLOSED

4:20 p.m. - 5:20 p.m.
XII. CLOSED SESSION

This portion of the meeting is being closed to the public in accordance with the provisions set forth in Sections 552b(c)(4), 552b(c)(6). Title 5 U.S. Code and 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2).

- INTRAMURAL SITE VISITS AND TENURE APPOINTMENTS
- PERSONNEL AND PROPRIETARY ISSUES

5:20 p.m.
ADJOURNMENT

WEDNESDAY, DECEMBER 3, 2003 - OPEN
Building 31, C Wing, Conference Room 10

8:00 a.m. - 10:00 a.m.
XIII. INTRAMURAL RE-ENGINEERING INITIATIVE  
  Dr. Barrett
10:00 a.m. - 10:15 a.m.

COFFEE BREAK

10:15 a.m. - 10:35 a.m.

XIV. THINK TANK TASK FORCES AND LONG RANGE SCIENTIFIC PLANNING  
Dr. Singer

10:35 a.m. - 11:35 a.m.

XV. NATIONAL BIO-SPECIMEN NETWORK INITIATIVES  
Dr. Barker

11:35 a.m. - 11:55 a.m.

XVI. BOARD STATUS REPORTS

• NCAB RETREAT REPORT  
Dr. Niederhuber

• SUBCOMMITTEE UPDATE(S)  
Members

11:55 a.m. – 12:00 noon

XVII. FUTURE AGENDA ITEMS  
Members

12:00 noon

ADJOURNMENT
SPEAKERS

Anna Barker, Ph.D.
Deputy Director
Strategic Scientific Initiatives
National Cancer Institute, NIH
Bethesda, MD

J. Carl Barrett, Ph.D.
Director
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD

Ms. Mary Anne Bright
Acting Deputy Director
Office of Communications
National Cancer Institute, NIH
Bethesda, MD

Ms. Nelvis Castro
Acting Director
Office of Communications
National Cancer Institute, NIH
Bethesda, MD

Peter Choyke, M.D.
Chief
Magnetic Resonance Imaging
Diagnostic Radiology Department
National Institutes of Health
Bethesda, MD

Ms. Susan Erickson
Acting Director
Office of Policy Analysis and Response
National Cancer Institute, NIH
Bethesda, MD

Mauro Ferrari, Ph.D.
Edgar Hendrickson Professor of Biomedical Engineering
Professor of Internal Medicine
Division of Oncology
Associate Vice President
Health Sciences Technology and Commercialization
Davis Heart and Lung Research Institute
The Ohio State University
Columbus, OH
Mr. John Hartinger
Associate Director
Office of Budget and Financial Management
National Cancer Institute, NIH
Bethesda, MD

Mr. Stephen Hazen
Chief
Extramural Financial Data Branch
Office of Budget and Financial Management
National Cancer Institute, NIH
Bethesda, MD

Eric Lander, Ph.D.
Professor of Biology
Director
Whitehead Institute Center for Genome Research
Massachusetts Institute of Technology
Cambridge, MA

LaSalle D. Leffall, Jr., M.D.
Charles R. Drew Professor of Surgery
Department of Surgery
Howard University College of Medicine
Howard University Hospital
Washington, DC

Crystal L. Mackall, M.D.
Head
Immunology Section
Pediatric Oncology Branch
National Cancer Institute, NIH
Bethesda, MD

Edward Maibach, Ph.D.
Director
Center for Strategic Dissemination
National Cancer Institute, NIH
Bethesda, MD

Andre Nussenzweig, Ph.D.
Senior Investigator
Recombination Section
Experimental Immunology Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD
Emmanuel Frank Petricoin, Ph.D.
Co-Director
NCI- FDA Clinical Proteomics Program
Senior Principal Investigator
Center for Biologics Evaluation and Research
Food and Drug Administration
Bethesda, MD 20892

Jeffrey Schlom, Ph.D.
Chief
Laboratory of Tumor Immunology and Biology
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD

Dinah Singer, Ph.D.
Director
Division of Cancer Biology
National Cancer Institute, NIH
Bethesda, MD

Lalage Wakefield, D. Phil.
Head
Tumor Suppressor Group
Laboratory of Cell Regulation and Carcinogenesis
National Cancer Institute, NIH
Bethesda, MD